Advanced search
1 file | 817.65 KB

Decoration of trastuzumab with short oligonucleotides : synthesis and detailed characterization

(2017) ORGANIC & BIOMOLECULAR CHEMISTRY. 15(42). p.8923-8928
Author
Organization
Abstract
Trastuzumab (Herceptin (R)) is an FDA-approved therapeutic antibody currently employed in the treatment of metastatic stages of breast cancer. Herein, we propose a simple, fast and cost-effective methodology to conjugate trastuzumab with 22-mer 5' thiol-modified oligonucleotides using a bifunctional crosslinker. The conjugates were successfully characterized by MALDI-ToF MS and SDS-PAGE, obviating the need for enzymatic digestion and difficult chromatographic separations. Furthermore, ELISA was performed to ensure that trastuzumab activity is not affected by oligonucleotide conjugation.
Keywords
DNA-DIRECTED IMMOBILIZATION, SENSITIVE ANTIGEN-DETECTION, IMMUNO-PCR, ANTIBODY, MICROARRAYS, PEPTIDE, COMBINATION, PLATFORMS, PROTEINS, CANCER

Downloads

    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 817.65 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Dias Carvalho Da Rocha, Ana Margarida, Alex Manicardi, C Véliz Montes, Smita Gunnoo, RJ Schneider, and Annemieke Madder. 2017. “Decoration of Trastuzumab with Short Oligonucleotides : Synthesis and Detailed Characterization.” Organic & Biomolecular Chemistry 15 (42): 8923–8928.
APA
Dias Carvalho Da Rocha, A. M., Manicardi, A., Véliz Montes, C., Gunnoo, S., Schneider, R., & Madder, A. (2017). Decoration of trastuzumab with short oligonucleotides : synthesis and detailed characterization. ORGANIC & BIOMOLECULAR CHEMISTRY, 15(42), 8923–8928.
Vancouver
1.
Dias Carvalho Da Rocha AM, Manicardi A, Véliz Montes C, Gunnoo S, Schneider R, Madder A. Decoration of trastuzumab with short oligonucleotides : synthesis and detailed characterization. ORGANIC & BIOMOLECULAR CHEMISTRY. 2017;15(42):8923–8.
MLA
Dias Carvalho Da Rocha, Ana Margarida, Alex Manicardi, C Véliz Montes, et al. “Decoration of Trastuzumab with Short Oligonucleotides : Synthesis and Detailed Characterization.” ORGANIC & BIOMOLECULAR CHEMISTRY 15.42 (2017): 8923–8928. Print.
@article{8541372,
  abstract     = {Trastuzumab (Herceptin (R)) is an FDA-approved therapeutic antibody currently employed in the treatment of metastatic stages of breast cancer. Herein, we propose a simple, fast and cost-effective methodology to conjugate trastuzumab with 22-mer 5' thiol-modified oligonucleotides using a bifunctional crosslinker. The conjugates were successfully characterized by MALDI-ToF MS and SDS-PAGE, obviating the need for enzymatic digestion and difficult chromatographic separations. Furthermore, ELISA was performed to ensure that trastuzumab activity is not affected by oligonucleotide conjugation.},
  author       = {Dias Carvalho Da Rocha, Ana Margarida and Manicardi, Alex and V{\'e}liz Montes, C and Gunnoo, Smita and Schneider, RJ and Madder, Annemieke},
  issn         = {1477-0520},
  journal      = {ORGANIC \& BIOMOLECULAR CHEMISTRY},
  keyword      = {DNA-DIRECTED IMMOBILIZATION,SENSITIVE ANTIGEN-DETECTION,IMMUNO-PCR,ANTIBODY,MICROARRAYS,PEPTIDE,COMBINATION,PLATFORMS,PROTEINS,CANCER},
  language     = {eng},
  number       = {42},
  pages        = {8923--8928},
  title        = {Decoration of trastuzumab with short oligonucleotides : synthesis and detailed characterization},
  url          = {http://dx.doi.org/10.1039/c7ob02216f},
  volume       = {15},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: